Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. reports developments across a diversified life sciences, diagnostics, genomics and consumer health portfolio. Recurring company updates include the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity tied to legacy COVID-19 testing receivables, and Nebula Genomics, including the DNA Complete direct-to-consumer whole genome sequencing platform.
PRPH news also covers capital-structure actions, convertible debt conversions, financing discussions, operating and financial results, governance matters, and the company’s trading-status transition from Nasdaq and the Pink Sheets to the OTC market. These updates frame ProPhase as an OTC-traded healthcare issuer with diagnostic, genomic data, consumer health, and receivables-related assets.
ProPhase Labs (OTC: PRPH) reported year-end 2025 results and an update on its Crown Medical Collections receivables platform.
The portfolio totals $201.2 million in gross claims across 649,205 claims; $79.9 million are in active negotiations and $121.3 million in open demand. The company estimates $50–$60 million potential net recoveries. Net revenue fell 27.6% to $4.9 million; net loss improved to $13.4 million. Nebula Genomics (DNA Complete) is now operating profitably on a standalone basis.
ProPhase Labs (OTC: PRPH) provided a March 17, 2026 business update on its Crown Medical Collections activity and related financing discussions. The company reports engagement with over 250 insurance payors, roughly 100 matters in active settlement discussions, and institutional diligence on receivables-backed financing.
ProPhase said potential financings may be secured by the receivables platform without recourse to the parent, and management is focused on stabilizing near-term liquidity while advancing Nebula Genomics/DNA Complete and the BE-Smart diagnostic.
ProPhase Labs (OTC: PRPH) has begun a potential sale or strategic partnership process for BE-Smart™, a CLIA-certified, CAP-accredited LDT for esophageal cancer risk stratification, and is advancing its Crown Medical Collections recovery initiative.
ProPhase completed a clinical/commercial dossier, has contacted more than 70 potential partners, cited a Mayo Clinic pilot showing high sensitivity, and estimates an addressable opportunity up to $14 billion. The company now believes > 60% of Crown Medical claims are underpaid (not denied), and reports rising interest in recovery-based, non-recourse financing that would be repaid from recoveries only.
ProPhase Labs (OTC: PRPH) invites investors to a live webinar on February 3, 2026 at 4:15 p.m. ET hosted by RedChip Companies featuring Chairman & CEO Ted Karkus. The presentation will review recent milestones including full U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test.
Other topics include a strategic initiative to recover more than $50 million in COVID-19 receivables, Nebula Genomics and planned commercialization of BE-Smart™, plus expansion of DNA Complete® and DNA Expand™ product lines.
ProPhase Labs (OTC: PRPH) provided an update on its Crown Medical Collections initiative for legacy COVID-19 testing receivables held by its lab subsidiaries in Chapter 11.
Crown Medical is engaged with 250+ insurance payors, with ~50 matters in advanced settlement posture and anticipated resolutions in 30–90 days (initial settlements expected Q1 2026). Labs billed ~$300M during COVID-19, with ~$150M unpaid or underpaid; aggregate net cash recoveries after fees could exceed $50M, subject to negotiation and court processes.
ProPhase Labs (OTC: PRPH) announced that its common stock was approved and uplisted from the Pink Sheets to the OTC market on January 22, 2026. The company said it expects the coming weeks to be an important inflection point and highlighted continued momentum in its Crown Medical collections initiative. ProPhase said it will provide a near-term operational update on Crown Medical and a strategic update on its BE-Smart® Esophageal Cancer Test. Management reiterated focus on executing core businesses and strengthening the company’s financial position to drive long-term shareholder value.
ProPhase Labs (OTC: PRPH) provided an update on recent capital‑structure activity, stock volatility, and underlying asset value on January 5, 2026. Management said >$3.3 million of convertible debt principal has converted (from $3.8 million issued), leaving less than $500,000 unconverted. Conversions occurred at a floor price of ~$0.76 per share, which the company says is above current trading levels, reducing near‑term conversion selling risk. The company completed a 1‑for‑10 reverse split and moved from Nasdaq to the OTC market; management said these technical events, plus accelerated conversions, drove temporary selling pressure but did not change the intrinsic value of operating assets.
Management emphasized debt reduction, a stronger balance sheet, and ongoing work on Crown Medical receivables, the BE‑Smart esophageal cancer diagnostic, and Nebula Genomics / DNA Complete.
ProPhase Labs (NASDAQ: PRPH) and Advanced Biological Laboratories entered a non-binding LOI on Dec 19, 2025 proposing a reverse merger that would make ABL majority owner (~76%) of the combined company.
The LOI is preliminary and subject to due diligence, definitive agreements, regulatory and Nasdaq approvals, and other conditions. A preliminary valuation framework implies a legacy ProPhase enterprise value of up to $30 million. ProPhase may declare a special cash dividend up to $10 million to shareholders of record (separate from the merged company). Crown Medical Collections receivables are expected to be carved out for current shareholders with anticipated collections of ≈$50 million net. The combined company would assume only agreed liabilities, currently contemplated to include $5 million of ProPhase indebtedness.
ABL Diagnostics reports that its controlling shareholder ABL S.A. and ProPhase Labs (Nasdaq: PRPH) have signed a non-binding letter of intent for a proposed reverse merger under which ABL would become the majority owner of the combined company.
The LOI is preliminary, creates no obligation to close, and is subject to due diligence, definitive agreements, regulatory approvals, and Nasdaq listing requirements. The parties target an indicative 60–90 day timeframe to execute definitive agreements. ABL S.A.’s control over ABL Diagnostics is unchanged and the proposal does not trigger the mandatory offer threshold based on available information.
The transaction may require ProPhase shareholder approval in the U.S. if a change of control occurs or if an issuance reaches 20% or more. The release is treated as inside information and will be archived for at least 5 years.
ProPhase Labs (NASDAQ: PRPH) will host an exclusive investor webinar on December 1, 2025 at 4:15 p.m. ET, hosted by RedChip Companies and featuring Chairman & CEO Ted Karkus.
The presentation will review ProPhase’s portfolio across molecular diagnostics, genomics, and consumer health, recent milestones including U.S. patent approval and clinical validation of the BE-Smart™ Esophageal Cancer Test, and a stated $7–14 billion addressable market for that test. Management will discuss a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 receivables, a streamlined cost structure, and the consumer genomics business Nebula Genomics with a large, diverse DNA dataset.
Planned near-term catalysts noted include commercialization of BE-Smart™ and expansion of DNA Complete® and DNA Expand™ product lines; a live Q&A follows. Registration is free via the RedChip webinar link.